Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.45 |
| ▸ | ADH1A | P07327 | 4/20 | 0.45 |
| ▸ | ADH1C | P00326 | 3/20 | 0.38 |
| ▸ | ADH7 | P40394 | 2/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10458654 | 1.00 | ADH1B (0.45) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL634247 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL11624219 | 0.74 | — | — | |
| SCHEMBL4117397 | 0.73 | — | — | |
| SCHEMBL2168792 | 0.73 | — | — | |
| SCHEMBL10457414 | 0.72 | ADH1B (0.50) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL13447716 | 0.72 | ADH1B (0.50) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL10457382 | 0.72 | ADH1B (0.50) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL10459102 | 0.72 | ADH1B (0.50) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL10459092 | 0.72 | ADH1B (0.50) | ADH1BADH1AADH1CADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321272-B1 | ORGANIC COMPOUNDS | NABRIVA THERAPEUTICS AG (AT) | 2016-04-20 | — | — | EP | disclosed |
| US-8222447-B2 | Organic compounds | NABRIVA THERAPEUTICS AG (AT) | 2012-07-17 | — | — | US | disclosed |
| US-8222447-B2 | Organic compounds | NABRIVA THERAPEUTICS AG (AT) | 2012-07-17 | — | — | US | disclosed |
| US-20110184022-A1 | Organic Compounds | NABRIVA THERAPEUTICS AG (AT) | 2011-07-28 | — | — | US | disclosed |
| US-20110184022-A1 | Organic Compounds | NABRIVA THERAPEUTICS AG (AT) | 2011-07-28 | — | — | US | disclosed |
| WO-2010025482-A1 | ORGANIC COMPOUNDS | NABRIVA THERAPEUTICS AG (AT) | 2010-03-11 | — | — | WO | disclosed |
| EP-2159220-A1 | Organic compounds | Nabriva Therapeutics AG (AT) | 2010-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184022-A1 | Organic Compounds | AHR, MAFK, MAFG | ADH1B 1362/4885ADH1A 884/4885ADH1C 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.